Madelin Millman's questions to Myriad Genetics Inc (MYGN) leadership • Q4 2024
Question
Madelin Millman, on behalf of Doug..., inquired about the 25% increase in R&D spending, its allocation to Precise MRD, and the implications for SG&A and overall operating expense guidance for 2025, including the 1000 basis point SG&A reduction target.
Answer
President and CEO Paul Diaz confirmed the accelerated R&D investment supports upcoming launches for FirstGene and Precise MRD. He explained that despite cost model adjustments due to the UnitedHealthcare decision, disciplined expense management and reallocation of funds to growth areas like R&D and technology will result in only a modest 3% overall increase in operating expenses year-over-year.